With the rapid growth of sequence databases, there is an increasing need for reliable functional characterisation and annotation of newly predicted proteins. To cope with such large data volumes, faster and more effective means of protein sequence characterisation and annotation are required. One promising approach is automatic large-scale functional characterisation and annotation, which is generated with limited human interaction. However, such an approach is heavily dependent on reliable data sources. The SWISS-PROT protein sequence database plays an essential role here owing to its high level of functional information.
INTRODUCTION
Although the ®rst complete sequence of an organism was determined some 22 years ago, the 5-kilobase sequence of the bacterial virus phi-X174 achieved by Sanger in Cambridge, 1 it is only in the last few years that the technology of sequencing has developed to the stage that the sequencing of the complete genome of a living organism can be contemplated as a practical and routine possibility. A major breakthrough was the sequencing of the ®rst complete eukaryote chromosome, chromosome III of Saccharomyces cerevisiae, in 1992 by an EU-funded consortium. 2 In 1995 the Institute of Genome Research (TIGR) group published the ®rst complete sequence of a bacterial genome, that of Haemophilus in¯uenzae. 3 Since those dramatic events the complete sequences of more than 30 bacterial genomes have been published and at least 70 more are known to be nearing completion. Not only has the complete sequence of S. cerevisiae been achieved, 4 but so has that of the nematode worm Caenorhabditis elegans 5 and of the fruit¯y Drosophila melanogaster, 6 and of the plant Arabidopsis thaliana, while the sequences of the yeast Schizosaccharomyces pombe and the sequences of several important protozoan parasites are well towards completion. In addition the complete genomes of many mitochondria and plastids have been determined. Largescale sequencing of the genome of the laboratory mouse is well underway, in both the USA and Europe. The`Holy Grail' of large-scale sequencing is, however, the determination of the sequence of the human genome, estimated at 3 billion base-pairs. The completion of the`®rst draft' of this sequence was announced on 26th June 2000.
All these projects produce large amounts of sequence data, lacking experimental determination of the biological function. To cope with such large data volumes, faster and more effective means of creating functional annotation are required. One promising approach is automatic annotation, which is generated with limited human interaction.
Several solutions of automatic functional characterisation of unknown proteins are based on high-level sequence similarity searches against known proteins. Other methods collect the results of different prediction tools in a simple 7 or more elaborate 8 manner. However, the currently used solutions have several drawbacks, such as the following:
· Since many proteins are multifunctional, the assignment of a single function, which is still common in genome projects, results in loss of information and outright errors.
· Since the best hit in pair-wise sequence similarity searches is frequently a hypothetical protein or poorly annotated or has simply a different function, the propagation of wrong annotation is widespread.
· There is no coverage of positionspeci®c annotation such as active sites.
· The annotation is not constantly updated and is thus quickly outdated.
It is also important to emphasise that a single sentence describing some predicted properties of an unknown protein should not be regarded as full annotation, but rather more as an attempt to characterise a protein. Full annotation means the combination of extracting experimentally veri®ed information from the literature with sequence analysis to add as much reliable and up-to-date information as possible about properties such as function(s) of the protein, domains and sites, catalytic activity, cofactors, regulation, induction, subcellular location, quaternary structure, diseases associated with de®ciencies in the protein, the tissue speci®city of a protein, developmental stages in which the protein is expressed, pathways and processes in which the protein may be involved, and similarities to other proteins.
THE ANNOTATION CONCEPT OF SWISS-PROT AND TrEMBL
The SWISS-PROT protein sequence database 9 strives to provide extensive annotation as de®ned above. However, owing to the increased data¯ow from genome projects to the sequence databases SWISS-PROT faced a number of challenges to its time-and labourintensive way of database annotation. Maintaining the high quality of sequence and annotation in SWISS-PROT requires careful and detailed annotation of every entry with information retrieved from the scienti®c literature and from rigorous sequence analysis. This is the rate-limiting step in the production of SWISS-PROT. On one hand it is desirable to keep the high editorial standards of SWISS-PROT. But that means that there is a limit to how much the annotation procedures can be accelerated. On the other hand, it is also vital to make new sequences available as quickly as possible. To address this concern, the European Bioinformatics Institute (EBI) introduced in 1996 TrEMBL (translation of EMBL nucleotide sequence database). TrEMBL consists of computer-annotated entries derived from the translation of all coding sequences (CDS) in the EMBL database, except for CDS already included in SWISS-PROT.
To enhance the annotation of uncharacterised protein sequences in TrEMBL, the SWISS-PROT/TrEMBL group at the EBI developed a novel method for the prediction of functional information. 10 This method selects proteins in the SWISS-PROT protein sequence database, which belong to the same group of proteins as a given unannotated protein, extracts the annotation shared by all functionally characterised proteins of this group, and assigns this common annotation to the unannotated protein.
AUTOMATIC ANNOTATION OF TrEMBL
To implement this methodology for the automated large-scale functional annotation of proteins three major components are required. First of all, a reference database must serve as the source of annotation. SWISS-PROT is used as the reference database because of its highly reliable, well-annotated and standardised information.
pitfalls of automatic annotation
Furthermore, a highly diagnostic protein family signature database must supply the means to assign proteins to groups. For this purpose PROSITE 11 was initially used, but since the beginning of 2001 InterPro 12 has been used to increase coverage and enhance reliability (reduction of false-positives and falsenegatives). This will mean coverage will be increased and reliability (reduction of false-positives and false-negatives) enhanced. InterPro is a new integrated resource for protein families, domains and functional sites, developed initially as a means of rationalising the complementary efforts of the PROSITE, PRINTS, 13 
Pfam
14 and ProDom 15 databases. By uniting these databases, it was possible to capitalise on their individual strengths, producing a single entity that is far greater than the sum of its parts. The use of InterPro allows the reliable classi®cation of proteins into families and the recognition of the domain structure of multidomain proteins. InterPro can classify currently around 60 per cent of all known protein sequences and this information is incorporated into SWISS-PROT and TrEMBL in the form of database cross-references to InterPro and its member databases.
The ®nal component needed for the implementation of our automated largescale functional annotation methodology is a database (RuleBase) that stores and manages the annotation rules, their sources and their usage.
The actual¯ow of information during the automatic annotation can be divided into ®ve steps:
· Use InterPro to extract the information necessary to assign proteins to groups (`conditions') and store the conditions in the RuleBase.
· Group the proteins in SWISS-PROT by the conditions.
· Extract from SWISS-PROT the common annotation shared by all functionally characterised proteins of each group and store this common annotation together with its conditions in the RuleBase. Now every rule consists of conditions and the annotation common to all proteins of this group characterised by these conditions.
· Group the unannotated TrEMBL entries by the conditions stored in the RuleBase.
· Add the common annotation to the unannotated TrEMBL entries. The predicted annotation will be¯agged with evidence tags, which will allow users to recognise the predicted nature of the annotation as well as the original source of the inferred annotation.
As the reliability of the conditions is crucial to the reliability of the methodology, a multiple-step procedure is used to minimise false positive automatic annotation: The automation of functional annotation is of paramount importance to mine the avalanche of sequence data. Our approach for the second generation of automated annotation will hopefully overcome some limitations of the existing automatic annotation methods:
· By using only the annotation from a reliable reference database for our predictions, the propagation of wrong annotation, one of the big problems in functional annotation, 16 will be drastically reduced.
· By using the`common annotation' of multiple entries, the implemented methodology will produce signi®cantly fewer over-predictions than methods based on the best hit of a sequence similarity search.
· Using the`common annotation' from a reliable reference database with standardised annotation and nomenclature allows the standardised annotation of uncharacterised proteins by avoiding the use of wrong nomenclature and of different descriptions for the same biological fact.
· Since the method will take both position-independent and positionspeci®c common annotation available in the reference database into account, a much higher level of annotation will be achieved, including position-speci®c annotation such as active sites.
· The`common annotation' approach can be used not only with protein families, but also with conditions aiming at a higher level in the protein family hierarchy. Only the annotation common to all members of this, for instance, super-family, will be copied over. The automatic annotation on a super-family level will obviously lead to more generic and limited annotation than on a family level.
· Our methodology is independent of the multidomain organisation of proteins. If a certain condition aims at a single domain that occurs with various other domains, it can be expected that only the annotation referring to this single domain will be found in all relevant characterised proteins. On the other hand, if the single domain always occurs with another domain, the information for the other domain will be picked up as well.
· The evidence tags will also allow the automatic update of the predicted annotation if the underlying conditions or the`common annotation' in the RuleBase changes. The SWISS-PROT format currently allows only one RP line of 75 characters (although this will change at a later date), and so we are not always able to list all experimentally determined 
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DE CD40 LIGAND (CD40-L) (TNF-RELATED ACTIVATION PROTEIN) (TRAP) (T CELL DE ANTIGEN GP39) (CD154 ANTIGEN).
Our example describes the protein as CD40 LIGAND'. That means that this protein has been experimentally characterised to be the`CD40 LIGAND'. With the increasing amount of data coming from mega-sequencing projects, more and more proteins in SWISS-PROT will be found with no experimental characterisation. These proteins can be identi®ed through their standardised labelling of the DE line.
All predicted protein sequences lacking any signi®cant sequence similarity to characterised proteins are labelled as hypothetical proteins'. The majority of these cases come from the genomesequencing projects. Example: When a protein exhibits extensive sequence similarity to a characterised protein and/or has the same conserved regions then the label`probable' is used in the DE line. It is normally followed by the full name of a protein from the same family that it matches. Example:
The label`putative' is used in the DE line of proteins that exhibit limited sequence similarity to characterised proteins. These proteins often have a conserved site, eg ATP-binding site, but no other signi®cant similarity to a characterised protein. It is most frequently used for sequences from genome projects. Example:
The assignment of the labels`probable' and`putative' is dependent primarily on the results of sequence similarity searches against SWISS-PROT and InterPro. It is important to point out here that no speci®c cut-off point is used to assign a protein as`putative' or`probable', i.e. it is not the case that , 50 per cent identity putative and . 50 per cent probable. An example illustrates why such assignments must involve curator judgments and cannot be based on speci®c cut-off points. Take the two Drosophila proteins Q9V5E3 (described as PROBABLE SERINE PROTEASE CG12133 (EC 3.4.21.-)') and Q9V4W6 (described as`CG8586 PROTEIN'). A FastA search of both of these protein sequences against SWISS-PROT results in both cases in dozens of highly signi®cant hits (with an E-value ± the assessment of statistical signi®cance based upon the extreme value distribution ± of e-9 or lower) against known proteases. Also, both proteins show Pfam trypsin (AC number PF00089) and PRINTS chymotrypsin (AC number PR00722) signatures. So both proteins seem to belong to the chymotrypsin serine protease family. However, only Q9V5E3 can be a real serine protease, since only in this protein you can ®nd both the serine (PROSITE AC number PS00135) and histidine (PROSITE AC number PS00134) active sites. Now let us move on to the SWISS-PROT CC lines. In SWISS-PROT entry P29965 you can ®nd the following CC lines: For features not experimentally veri®ed, SWISS-PROT uses the same labelling conventions as already described above for the CC lines. In our example it is known that this is glycosylated, disulphide bonds containing type II membrane protein, but the correct topology of the protein, the glycosylation site(s) and the disul®de bonds have not been experimentally con®rmed. The label`potential' is used to indicate the predicted character of the information given in the features`DOMAIN', DISULFID' and`CARBOHYD'. Another label used to indicate that a feature has not been experimentally proven is`by similarity'. This label indicates that this feature has been assigned because of similarity to an existing characterised entry. Table 2 summarises the rules used tō ag annotation added to entries where no, or only limited, experimental evidence is available.
CONCLUSION
The addition of functional information to SWISS-PROT and TrEMBL protein sequence entries is a time-and labourintensive process. Great care is taken to ensure that the information added can be traced either to the relevant data source or back to the entry (or entries) reporting the experimentally determined characteristics. This effort is necessary as the exploitation of the sequence avalanche is heavily depending on reliable data sources as the basis for automatic large-scale functional characterisation and annotation by comparative analysis. The ongoing inclusion of additional functional information and a further improved labelling of the annotation in SWISS-PROT and TrEMBL with more advanced and rigorous evidence tagging will be of great importance for the development of new automatic annotation systems able to achieve a much higher level of accurate predicted annotation than today. By similarity CC Experimentally proven in member of the same family to which the new entry is believed to belong. FT From alignment the domain/site exists and the sequence it is aligning against has the domain/site experimentally proven.
